12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afinitor everolimus regulatory update

The U.K.'s NICE issued final guidance recommending against Afinitor everolimus from Novartis for second-line treatment of advanced renal cell carcinoma (RCC). The agency said it could not recommend Afinitor as a cost-effective use of NHS resources despite a revised patient access scheme in a November final appraisal determination (FAD) and satisfying the criteria...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >